Don joined Advent in 2007 after 25 years as a biotech entrepreneur and chief executive. He co-founded Medarex, Genmab, and Celldex Therapeutics, all of which grew to be multi-billion dollar companies.

Don has overseen the progression of numerous innovative therapeutics from research concept to clinical trials, including the pioneering cancer treatments Yervoy® and Opdivo®, which were recognized in the 2018 Nobel Prize.

Don is a Fellow in Health Management and co-lead of the Biopharmaceutical Initiative at the University of Cambridge Judge School of Business. He is also a co-author of the book From Breakthrough to Blockbuster: The Business of Biotechnology, a Financial Times Top Business Title. He received an AB from Dartmouth College, a JD from Columbia University and a PhD from Princeton University.

Don takes Advisory, Board and senior non-executive roles with our portfolio companies, including 4-antibody, Capella Biosciences, Aleta, and Manta Medicines.

Back to Team